Resource Centre

Assessing how your drug interacts with other drugs in vivo is a critical step in the drug development process and is essential in ensuring safe and efficacious drug delivery. This assessment is known as a drug-drug interaction (DDI) study and is a regulatory requirement for submissions of investigational new drugs (INDs). Learn more about Quotient Sciences' offering for DDI studies.

Quotient Sciences has expertise in developing, manufacturing, testing, releasing, and supplying a range of formulations (IV, SC, and IM administration) for a variety of clinical study types, including first-in-human (FIH) healthy volunteer studies assessing safety, tolerability, and pharmacokinetics (PK), as well as radiolabeled formulations for human absorption, distribution, metabolism, and excretion (ADME) studies.

Integrated programs that bridge molecules from early discovery to proof of concept (POC) and beyond.

Peptide drug products continue to gain popularity in the pharmaceutical industry due to their high selectivity, high potency, and good safety profile. However, formulating peptides can present many challenges for drug developers because of their unique physicochemical properties.

With over 30 years of formulation expertise and over 100 MR programs developed, the team at Quotient Sciences possess the experience, capabilities, and technologies needed to create a successful MR formulation.

With over 30 years’ experience as a world leading provider of human ADME 14C radiolabeled studies, we have the scientific expertise and operational know-how to design and deliver human ADME programs in preparation for NDA, MAA and global regulatory filings.

Simplify early development and accelerate to Proof-of Concept Proof-of-Concept (POC) is a key milestone in the development of a new drug candidate. At Quotient Sciences, we understand the increasing pressures on R&D budgets, therefore the need to transition molecules through early development to POC needs to be fast and cost-effective.

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Our corporate brochure provides a key summary of who we are, what we represent, our services and our marketplace differentiation.

Designated team of highly experienced personnel who control all aspects of sample management and liaise closely with clients throughout the lifecycle of stability studies. Our aim is to provide robust, sound data on which shelf life and expiration dates for drug substance and drug products can be based. Whatever the phase of development our team can offer support. We also offer a stability protocol creation service if clients prefer not to supply stability protocols themselves. Robust systems are in place to ensure complete tracking of samples from receipt, through stability storage and time-point testing (or shipment if required), to study end.

Quotient Sciences' extensive experience permits testing of difficult products that have not previously been analyzed. We are specialists at the microbial analysis of radiolabelled compounds and are able to handle cytotoxic, high potency compounds and controlled substances. Our flexible approach allows us to offer both on-site microbiological testing and analysis of products made off-site.

Whether you need isotopically labelled (14C/SIL) compounds for nonclinical or clinical metabolism studies and the quantification of materials in biological matrices, our expertise provides the necessary labelled materials tailored to support your studies.

Determining drug exposure is vital for the assessment of drug safety and efficacy. Quotient Sciences Bioanalytical team develop and refine methods so exposure can be assessed reliably and accurately in a variety of biological matrices.